Tag Archive for: CFTX-1554

Confo Therapeutics' CEO Cedric VerverkenConfo Therapeutics NV
financing

Confo Therapeutics closes €60m Series B financing

Belgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.

Read more
Confo Therapeutics' management team: Toon Laeremans (Head of Technology); Cedric Ververken (CEO); Christel Menet (CSO); Frank Landolt (Chief Counsel IP & Legal). © Confo Therapeutics
partnership

Confo Therapeutics and Lilly partner to advance CFTX-1554

Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.

Read more